Pharma BD Deal Intelligence
A licensing deal disguised as an acquisition: LEO Pharma's tralokinumab bet paid off as a genuine dermatology growth driver.
Full analysis, sources & comparables →Straightforward factual account of the licensing terms: 'LEO Pharma will make an upfront payment to AstraZeneca of $115 million' plus milestones and royalties;…
Presented as strategically positive for both companies: AstraZeneca focuses resources on core respiratory areas while LEO expands into biologics. Aabo: 'By…
AstraZeneca's Luke Miels: 'This agreement allows us to concentrate our efforts on tralokinumab's potential for patients with severe asthma, a priority area for…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
LEO Pharma paid AstraZeneca $115M upfront for exclusive global rights to tralokinumab in atopic dermatitis (and any future dermatology indications) plus exclusive European rights to brodalumab in psoriasis. Up to $1B in commercial milestones and mid-teen tiered royalties on tralokinumab. Allowed AstraZeneca to focus tralokinumab on severe asthma; LEO entered biologics. Tralokinumab later approved as Adbry/Adtralza.
A licensing deal disguised as an acquisition: LEO Pharma's tralokinumab bet paid off as a genuine dermatology growth driver.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| LEO Pharma A/S / AstraZeneca PLC (this deal) | 2016 | $1.1B | 80 |
| LEO Pharma A/S / Replay Holdings LLC | 2026 | $50M | — |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
← Browse all deals · How we score deals
More: 2016 deals · Dermatology deals